Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.

50 Notwithstanding that many other studies demonstrated a favorable trend with the implementation of adjuvant chemotherapy on patients with MSI-H/dMMR, the final results remained non-significant. 51 For example, in a study performed by Tsai and colleagues, 36 although patients who received adjuvant chemotherapy showed better 5 year disease-free survival (DFS) (61.2% vs. 55.9%), no significant benefit was found for postoperative adjuvant chemotherapy of MSI-H/dMMR gastric cancer [DFS, HR 0.64 (0.21–1.94) and OS, HR 0.8 (0.35–1.82)].

also in 1,005 other papers